{
    "2018-12-07": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Novartis Presents Additional Data on Breast Cancer Candidate",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Breast Cancer",
                        "Candidate",
                        "Additional Data"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Generic drugmaker Sandoz to sell alternative to EpiPen injectors",
                "features": {
                    "keywords": [
                        "Sandoz",
                        "EpiPen",
                        "Generic",
                        "Alternative"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Novartis to launch Adamis' EpiPen rival in U.S. next year",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Adamis",
                        "EpiPen",
                        "Rival",
                        "Launch"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}